ELIAS CASTANAS

(October 2004)

1. General Information

 

Date of Birth

 

1 January 1952

Birthplace

 

Athens, Greece

Nationality

 

Greek, Fench

Marital State

 

Married, Two Children

Address     Work

 

 

               Tel.

               Fax.

               e-mail

Laboratory of Experimental Endocrinology

School of Medicine

GR-71110, Heraklion, Crete, Greece

+30-81-394580

+30-81-394581

castanas@med.uoc.gr

 

2. Studies

 

University

University of Athens

School of Medicine

1969-1975

 

ECFMG

 

June 1975

 

Doctoral Thesis

 

University of Athens

School of Medicine

February 1978


3. Postgraduate Studies

 

Specialty in Endocrinology

     and Metabolism

University Aix-Marseille II

Faculty of Medicine

June 1981

 

 

Specialty in Biochemistry-

Molecular & Cellular Biology

University of Aix-Marseille II

Faculty of Sciences

September 1981

 

 

PhD Thesis

University od Aix-Marseille II

Faculty of Sciences

September 1981

 

 

These d'Etat es Sciences

     (Doctorate in Sciences)

University od Aix-Marseille II

Faculty of Sciences

June 1985

 

 

Use of Radioelements

CEA, Saclay, France

June 1983

 

                       
4. Languages

 

Uses fluently Greek, French, English.

 

5. Positions Held

 

1970-1975

Research and Teaching Associate University of Athens, School  of Medicine Laboratory of Biological Chemistry

 

 

 

1975-1978

Research and Teaching Assistant University of Athens, School of Medicine Laboratory of Biological Chemistry.

 

 

1978-1980

Assistant in Endocrinology and Metabolism, Endocrinology and Metabosism Clinic, University Aix-Marseille II.

 

 

1980-1985

University Assistant (Assistant des Sciences Fondamentales) University Aix-Marseille II Faculty of Medicine Laboratory of Biochemistry.

 

 

1985- 1997

Research Associate (Charge de Recherche INSERM) Laboratory of Experimental Neuroendocrinology, U 297, Marseille

 

 

1987-1993

 

 

1993-

Associate Professor of Experimental Medicine (Endocrinology), University of Crete, School of Medicine

Professor of Experimental Endocrinology

 

 

1989-1992

Director of the Clinical Chemistry Laboratory, University Hospital of Heraklion, Crete

 

1989-

 

Director of the Experimental Endocrinology and Immunology Department, University Hospital of Heraklion, Crete

 

1996-

 

Corresponding Member of the American Association for Cancer Research

 

1996-

 

Greek Representative for the European Union Action COST 825 (Mammary Gland Research)

 

1997-

 

Member of the Scientific Committee of the Hellenic Pasteur Institute

 

 

6. Publications

 

 

1975

 

1. Kaniaris P., Lekakis D., Mykoniatis M., CASTANAS E. Serum free-fatty acids and blood glucose levels in children under halothane, thiopentone, and ketamine anesthesia (comparative study). Canad. Anaesth. Soc. J. 22: 509-515

 

2. Kaniaris P., Katsilambros N., CASTANAS E., Theophanidis C. Relation between  glucose tolerance and serum insulin levels in men, before and after thiopental I.V. administration. Anesthesia Analgesia (C.R.) 54: 718-723.

 

 

1977

 

1. Kaniaris P., Hambouri O., Tsoumplekou E., CASTANAS E. Relation between ethrane and renal function. Arch. Med. Soc. (Greece) 2: 425-428.

 

2. CASTANAS E., Livanou Th., Oikonomidou I, Sofroniadou K. Enzymatic determination of GTP and LDH in thalasemia. Arch. Med. Soc. (Greece) 2: 215-218.

 

3. CASTANAS E., Papastratis G., Margioris A., Carydakis P., Kakaviatos  N., Antypas G., Livanou Th. The influence of pharmaceutical vagotomy on serum gastrin and plasma cyclic nucleotide levels. in "Interdisciplinary Trends in Surgery" Minerva Medica Eds. pp 949-960

 

 

1978

 

1. CASTANAS E. Metabolic Changes in Thalasemia. Doctoral Thesis, Athens.

 

 

1979

 

1. Carayon P., CASTANAS E., Guibout M., Codaccioni J.-L. Assessment and clinical significance of free thyroid hormone radioimmunoassays. in: R. Ekins, G. Faglia, F. Penisi, A. Pinchera (eds) "International Symposium on free thyroid hormones" Excepta Medica, pp 181-205.

 

2. Codaccioni J.L., Carayon P., CASTANAS E., Guibout M. Clinical interest of direct radio-immunological determination of free thyroid hormone plasma levels. in "Radioimmunology 1979" C.A. Bizolon (ed) Elsevier-North Holland pp 97-107

 

 

1980

 

1. Carayon P., Thomas-Morvan C., CASTANAS E., Tubiana M. Human thyroid cancer: Membrane thyrotropin binding and adenylate cyclase activity. J. Clin. Endocrinol. Metab. 51: 915-918.

 

2. CASTANAS E. Etude longitudinale des differentes parametres de surveillance biologique apres traitement radical de la maladie de Basedow. Research Dissertation for the obtention of the specialty of Endocrinology and Metabolism. University Aix-Marseille II.

 

 

1981

 

1. Conte-Devolx B., Giraud P., CASTANAS E., Boudouresque F., Orlando M., Gillioz P., Oliver C. Effect of neonatal treatment with monosodium glutamate on the secretion of α-MSH, β-endorphin and ACTH in the rat. Neuroendocrinology 33: 207-211.

 

2. Conte-Devolx B., Oliver C., Giraud P., Gillioz P., CASTANAS E., Lissitzky J.-C., Boudouresque F., Milliet Y. Effect of nicotine on the secretion of melanocorticotropic hormones in the rat. Life Sci. 28: 1067-1073.

 

3. CASTANAS E. Heterogeneite des formes hormonales secretees par des adenomes a prolactine. These de IIIe Cycle.  Ph D Thesis, University Aix-Marseille II.

 

 

1982

 

1.Conte-Devolx B., Oliver C., Giraud P., CASTANAS E.,Boudouresque F., Gillioz P., Milliet Y.

Adrenocorticotropin,  β-endorphin and corticosterone secretion in Brattleboro rats. Endocrionology 110: 2097-2100.

 

2. Conte-Devolx B., Oliver C., Foucault-Chiozza F., Giraud P., CASTANAS E., Codaccioni J.-L. Effets de la 1-desamino-8-D-arginine-vasopressine sur la fonction corticotrope de l'homme. Nouv. Presse Med. 11: 2566-2567.

 

3. Giraud P., CASTANAS E., Oliver C., Eiden L. E., Boudouresque F., Jaquet P., Conte-Devolx B., Cesselin F. Mise en evidence d'enkephalines dans les pheochromocytomes. Arch. Mal. Coeur (suppl) 143-146.

 

4. Giraud P., CASTANAS E., Conte-Devolx B.,á Boudouresque F., Taquet H., Orlando M., Jaquet P., Eiden L. E., Cesselin F., Gunz G., Trigano M.  Enkephalins in human pheochromocytoma: Biosynthesis and secretion. Europ. Heart J. 3: 19-22.

 

5. Conte-Devolx B., Rey M., Boudouresque F., Giraud P., CASTANAS E., Milliet Y., Codaccioni J.-L., Oliver C.  Effet de l'immunisation passive avec un serum anti-CRF sur la secretion d'ACTH du rat. C. R. Acad. Sci. (Paris) 295: 647-650.

 

6. Rey M., Conte-Devolx B., Grillo J.-M., CASTANAS E., Mersier G-M., Boudouresque F., Giraud P., Milliet Y., Oliver C. Effet de la stimulation electrique du noyau paraventriculaire (NVP) sur la fonction corticotrope du rat Long-Evans et Brattleboro. C. R. Acad. Sci. (Paris) 295: 597-599.

 

7. Giraud P., Eiden L. CASTANAS E., Conte-Devolx B., Boudouresque F., Jaquet P., Oliver C.

Peptides opiaces de la medullosurrenale. Nouv. Presse Med. 11: 1867-1872.

 

 

1983

 

1. Giraud P., CASTANAS E., Patey G., Oliver C., Rossier J. Regional distribution of Methionine Enkephalin-Arg6-Phe7 in the rat brain: Comparative study with the distribution of other opioid peptides. J. Neurochem. 41: 154-160.

 

2. CASTANAS E., Giraud P., Audigier Y., Drissi R., Boudouresque F., Conte-Devolx B., Oliver C. Opiate binding sites on bovine adrenal medulla and six human pheochromocytomas. Life Sci. 33(1): 295-298.

 

3. Conte-Devolx B., Rey M., Boudouresque F., Giraud P., CASTANAS E., Milliet Y., Codccioni J-L., Oliver C. Effect of 41-CRF antiserum on the secretion of ACTH, β-endorphin and α-MSH in the rat. Peptides 44: 301-304.

 

4. Oliver C., Conte-Devolx B., Giraud P., CASTANAS E., Boudouresque F., Gunz G. Dopaminergic system and hypophyseal function. in "Special Aspects of Psychopharmacology" M. Ackenheil and N. Matussek (eds) Expansion Scientifique Francaise, pp 257-267.

 

5. Boudouresque F., Trigano M., Conte-Devolx B., Giraud P., CASTANAS E., Gunz G., Oliver C. Formes moleculaires de l'ACTH hypophysaire et plasmatique en physiologie et pathologie. Ann. Endocrinol. 44: 9-14.

 

 

 

1984

 

1. CASTANAS E., Giraud P., Audigier Y., Drissi R., Boudouresque F., Conte-Devolx B., Oliver C. Adrenal medullary opiate receptors: Pharmacological characterization in bovine adrelal medulla and a human pheochromocytoma. Mol. Pharmacol. 25: 38-45.

 

2. CASTANAS E., Giraud P., Drissi R., Chabrier P.-E., Conte-Devolx B., Boudouresque F., Cantau P., Cesselin F., Cupo A., Eiden L. E., Oliver C. Characterization of enkephalins and related peptides in rat hypophyseal portal blood. Brain Res. 310: 1-6.

 

3. CASTANAS E., Giraud P., Bourhim N., Cantau P., Oliver C. Kappa 3: a novel subtype of the kappa opioid site in the bovine adrenal medulla, highly selective for Met-enkephalin-Arg6-Phe7. Neuropeptides 5: 133-136.

 

4. Boudouresque F., Dutour A., Conte-Devolx B., CASTANAS E., Ouafik L., Codaccioni J.-L., Oliver C. Significationá d'un taux eleve d'ACTH en discordance avec la clinique et le reste de la biologie. Rev. Fr. Endocrinol.Clin. 25: 231-235.

 

 

1985

 

1. Conte-Devolx B., Oliver C., CASTANAS E., Rey M., Guillaume V., Boudouresque F., Giraud P. La corticoliberine. Presse Med. 14: 737-742.

 

2. CASTANAS E., Bourhim N., Giraud P., Boudouresque F., Cantau P., Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I Interaction with delta and mu sites. J. Neurochem. 45: 677-687.

 

3. CASTANAS E., Bourhim N., Giraud P., Boudouresque F., Cantau P., Oliver C. Interaction of opiates with opioid binding sites in the bovine adrenal medulla: II Interaction with kappa sites. J. Neurochem. 45: 688-699.

 

4. Bourhim N., CASTANAS E., Giraud P., Cantau P., Oliver C. Modification of opioid ligand binding in the central and the peripheral nervous system by different buffers. Biochem. Biophys. Res. Commun. 129: 328-333.

 

5. CASTANAS E., Jaquet P., Gunz G., Cantau P., Giraud P. Direct action of opiates on bromocriptine-inhibited prolactin release by human prolactinoma cells in culture. J. Clin. Endocrinol. Metab. 61: 963-986.

 

6. Blanc D., Cupo A., CASTANAS E.,á Bourhim N., Giraud P., Eiden L. E. Influence of acute, subchronic and chronic treatment with neuroleptics (haloperidol) on enkephalins and their precursors in the striatum of rat brain. Neuropeptides 5: 567-570.

 

7. Conte-Devolx B., Grino M., Nieoullon A., Javoy-Agid F., CASTANAS E., Tonon M.-C., Guillaume V., Oliver C. Corticoliberine (CRF), somatostatin (SRIF), somatocrinin (GRF) and amines content in normal human hypothalamus and in patients with Parkinson's disease. Neurosci. Letts 56: 217-222.

 

8. Ouafik L'H., Dutour A., CASTANAS E., Boudouresque F., Oliver C. Evidence for a precursor of TRH in the neonatal rat pancreas. Biochem. Biophys. Res. Commun. 128: 664-669.

 

9. Dutour A., Ouafik L'H., CASTANAS E., Boudouresque F., Oliver C. TRH and TRH-OH in the pancreas of adult and newborn rats. Life Sci. 37: 177-183.

 

10. CASTANAS E. Les sites de liaison opiaces: Le modele medullosurrenallien. These d'Etat es Sciences Naturelles. Doctorate in Sciences Thesis, University Aix-Marseille II.

 

 

1986

 

1. CASTANAS E., Blanc D., Bourhim N., Cupo A., Cantau P., Giraud P. Reassessment of opioid binding sites in different areas of the rat brain. Neuropeptides 7: 369-380.

 

2. Carydakis C., Bourhim N., Giraud P., Cantau P., Oliver C., CASTANAS E. Les antidepresseurs tricycliques interagissent directement avec les sites de liaison opiaces dans la medullosurrenalle bovine. C. R. Acad, Sci. (Paris) 302: 419-422.

 

3. Ouafik L'H., Dutour A., Salers P. Giraud P., Boudouresque F., CASTANAS E., Oliver C. Evidence for high peptide α-amidation activity in the neonatal rat pancreas. Biochem. Biophys. Res. Commun. 138: 179-184.

 

4. Nordmann J-J., Cazalis M., Danidji G., CASTANAS E., Giraud P., Legros J., Louis F. Are opioid peptides co-localized with vasopressin or oxyticin? Cell Tissue Res. 246: 177-182.

 

5. Giraud P., Affolter H.-U., Hotchkiss A., CASTANAS E., Oliver C. Eiden L. E. Regulation de la biosynthese des enkephalines dans les cellules chromaffines. Ann. Endocrinol. (Paris) 47: 40-42.

 

6. Leboulenger F., Cupo A., CASTANAS E., Benyamin M., Pelletier G., Vaudry H. Immunohistochemical and biochemical evidence for the presence of the pentapeptide Met-enkephalin and the heptapeptide Met-enkephalin-Arg6-Phe7, but not the octopeptide Met-enkephalin-Arg6-Gly7-Leu8 in amphibian chromaffin cells. Neurochem. Int. 8: 303-309.

 

7. Grino M., CASTANAS E., Guillaume V., Boudouresque F., Conte-Devolx B., Oliver C. Binding sites for rat corticotropin releasing factor: evidence for heterogeneity and modulation by glucocorticoids. Exp. Clin. Endocrinol. 5: 63-68.

 

8. Grino M., CASTANAS E., Conte-Devolx B., Guillaume V., Boudouresque F., Oliver C. Caracterisation et modulation des sites de liaison antehypophysaires a la corticoliberine de rat (r-CRF). Ann. Endocrinol. (Paris) 47: 51-53.

 

9. Ouafik L'H., Dutour A., Giraud P., Boudouresque F., CASTANAS E., Oliver C. Mise en evidence d'un precurseur pour la TRH dans le pancreas du rat nouveau-ne. Ann. Endocrinol. (Paris) 47: 43-44.

 

10. Guillaume V., Dutour A., Ouafik L'H., CASTANAS E., Oliver C. Immunoreactive TRH and TRH-OH in rat hypophyseal portal blood. in "Progress in Thyroid Research" G. Madeiros-Neto and E Gaitan (eds), Plenum Press (New York & London) Vol 1, pp 295-298.

 

 

 

1987

 

1. Ouafik L'H., Giraud P., Salers P., Dutour A., CASTANAS E., Boudouresque F., Oliver C. Evidence for high peptide ÿ-amidation activity iná the pancreas from neonatal rats. Proc. Natl. Acad. Sci. (USA) 84: 261-264.

 

2. Cantau P., Bourhim N., Giraud P., Oliver C., CASTANAS E. Photoaffinity crosslinking of etorphine with opioid binding sites in the bovine adrenal medulla. Biotechnol. Appl. Biochem. 9: 114-122.

 

3. Grino M., Guillaume V., CASTANAS E., Boudouresque F., Conte-Devolx B., Oliver C. Effect of passive immunization against corticotropin releasing factor (CRF) on the postadrenalectomy changes of CRF binding sites in the rat anterior pituitary gland. Exp. Clin. Endocrinol. 5: 63-68.

 

4. CASTANAS E. Lecture Notes in Pharmacology. Ηεraκlion

 

 

1988

 

1. CASTANAS E. Lecture Notes in Clinical Chemistry. General Methods. Ηεraκlion.

 

2. Karydakis P., Papastratis G., Alexiou D., CASTANAS E., Skalkeas G. Le role de l'AMP cyclique dans la secretion gastrique: Mecanisme d'action de la pentagastrine et de la cimetidine. J. Chir. (Paris) 125: 484-490

 

1989

 

1. Laboratory of Clinical Chemistry-Biochemistry University Hospital of Heraklion. Notes on the use of Clinical Chemistry Examinations.

 

 

1992

 

1. Hatzoglou A.,  Prekezes J., Tsami M., CASTANAS E. (1992) Protein measurement of particulate and solubilized ovine liver membranes. Ann. Clin. Biochem. 29 659-662

 

1993

 

1. Bourhim N., CASTANAS E., Giraud P., Oliver C. Differential modulation of solubilized opioid binding sites by cations in the bovine adrenal medulla. Mol. Neuropharmacol. 3, 139-146

 

2. Bourhim N., Cantau Ph., Giraud P., CASTANAS E. Comparative thermodynamics of opioid receptor-ligand interaction in the bovine adrenal medulla membranes: Evidence of opioid site heterogeneity. Compar. Biochem. Physiol. 104B, 607-615

 

3. CASTANAS e., Hatzoglou A. Biological factors with diagnostic or prognostic value in breast cancer. Iatriki, 66, 264-276

 

4. Papavasiliou S., CASTANAS E., Kalmanti M. Leydig cell function in boys with testicular relapse of acute lymphocytic leukemia. Il Friuli Medico-Alpe Adria J. Med. 48: 43-47.

 

5. Hatzoglou A., Prekezes I., CASTANAS E.  Protein assay in membrane preparations: Comparison of different methods. Arch. VI Congress of the Cretan Medical Society) 414-416

 

6. Hatzoglou A., Romain S., Martin P-M., Vlachonikolis J., CASTANAS E. Biological parameters of primary and metastatic breast cancer. Arch. VI Congress of the Cretan Medical Society 378-381

 

7. Hatzoglou A., Dalapascha E., CASTANAS E. A new method for the assay of EGF receptors in microsamples (accidification). Comparison of availlable techniques. Arch. VI Congress of the Cretan Medical Society 411-413

 

8. Kolyvaki S., Tampakaki M., CASTANAS E. Modifications and initial clinical findings of an ELISA for human Erythropoietin in serum. Arch. VI Congress of the Cretan Medical Society 417-419

 

9. Kremasmenou E., Kolyvaki S., Ampatzaki V., Kafatos A., CASTANAS E. Physiological variations of immunological parameters in the rural and civil population in Crete, Greece. Arch. VI Congress of the Cretan Medical Society 64-66

 

 

 

1994

 

1. Hatzoglou A., Romain S., Dalapascha H., CASTANAS E. Acidification reveals a greater number of Epidermal Growth Factor Receptors in human membrane preparations. Cli. Chim. Acta 227, 97-109

 

1995

1. Krambovitis E., Hatzidakis G., Hatzoglou A., Romain S., Durand A., Stefanakis A., CASTANAS E. An enzyme-ligand immunoassay for simmultaneous quantitation of estrogen and progesterone receptors in breast cancer microsamples. Clin. Chem. 41, 48-53

2. Hatzoglou A., Gravanis A., Zoumakis E., Margioris A., CASTANAS E. Identification and characterization of opioid binding sites  present in the Ishikawa human endometrial adenocarcinoma cell line. J. Clin. Endocrinol. Metab. 80, 418-423

3. Papavasiliou S., Brue Th., Jaquet Ph. CASTANAS E. Non Linear Analysis of the Dynamics of Prolactin diurnal secretion in man: Findings, conclusions aid implications. Neuroendocrinol. 62, 444-453

4. Hatzoglou A., Ouafik L’H., Bakogeorgou E., Thermos K., CASTANAS E. Morphine cross-reracts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line, and decreases cell proliferation. Cancer Res. 55, 5632-5636

 

 

 

1996

 

1. Hatzoglou A., Bakogeorgou E. CASTANAS E. The antiproliferative effect of opioid agonistss on the T47D human breast cancer cell line, is partially mediated through opioid receptos. Eur. J. Pharmacol. 296, 199-207

 

2. Hatzoglou A., Bakogeorgou E., Hatzoglou Ch., Martin P.M., CASTANAS E. Antiproliferative and Receptor binding properties of α- and β- casomorphin peptides, in the T47D human breast cancer cell line. Europ. J. Pharmacol. 310, 217-223.

 

3. Hatzoglou A., Margioris A., Bakogeorgou E., Gravanis A., CASTANAS E. Identification, Characterization and localisation of Corticotropin-Releasing Hormone Receptors in Human Placenta. Life Sci. 59, 1871-1879.

 

4. Hatzoglou A., Bakogeorgou E., Stournaras C., Emmanuel D., CASTANAS E. Identification and  characterisation of opioid and somatostatin binding sites in the Kidney Oposum (OK) cell line, and their effect on growth. J. Cell. Biochem. 63, 410-421

 

5. Kampa M., Loukas S., Hatzoglou A., Martin P., Martin P-M., CASTANAS E. Identification of a novel opioid peptide derived from alpha-S1 human casein (alpha-S1 casomorphin, and alpha-S1 casomorphin-amide) Biochem. J. 319, 903-908.

 

6. Chinot O., Kircher C., Romain S., CASTANAS E., Martin P-M. Les Merqueurs tumoraux. In “Le praticien face au cancer du sein. Arnette-Blackwell Publ. Paris pp 163-177.

 

1997

 

1.       Bakogeorgou E., Hatzoglou A., CASTANAS E. Taxol interacts with opioid binding sites in the T47D human breast cancer cell line. Biochem. Biophys. Res. Commun. 235, 201-204

 

2.       Kampa M., Bakogeorgou E., Hatzoglou A., Damianaki A., Martin P-M., CASTANAS E. Opioid alkaloids and casomorphin peptides decrease prostatic cancer cell line (LNCap, PC3 and DU145) proliferation through a partial interaction with opioid receptors. Eur. J. Pharmacol. 335, 255-266

 

3.                   Alexandrakis M., Coulocheri S.,Kyriakou D., Bouros D., Xirouhaki N., Siafakas N., CASTANAS E., Eliopoulos G. Diagnostic value of ferritin, haptoglobin, α1-antitrypsin, lactate dehydrogenase and complement factors C3 and C4 in pleural effusion differentiation. Respir. Med. 91, 517-523.

 

 

1998

 

 

1. Petinaki E., Nikolopoulos S., CASTANAS E. Low stimulation of peripheral lymphocytes, following in vitro application of Emdogain. J. Clin. Periodontol. 25, 715-20

 

2. Papakonstanti E.A., Bakogeorgou E., CASTANAS E., Emmanouel D.S., Hartig R., Stournaras C. Early alterations of actin cytoskeleton in OK cells by opioids. J. Cell. Biochem. 70, 60-69

 

3. Panagiotou S., Hatzoglou A., Calvo F., Matrin P-M., CASTANAS E. Modulation of the estrogen-regulated proteins cathepsin D and pS2 in hormone-sensitive breast cancer cell lines (MCF7 and T47D) by opioid agonists: Evidence for an interaction between the two systems. J. Cell. Biochem. 71, 416-428

 

 

 

1999

 

 

1. Kampa M., Margioris A.N., Hatzoglou A., Dermitzaki E., Gravanis A., Henry J-F., Oliver C., CASTANAS E. Kappa1 are the dominant opioid binding sites in surgical specimens of human pheochromocytomas and a human pheochromocytoma (KAT45) cell line. Europ. J. Pharmacol. 364, 255-262

 

2. Panagiotou S., Bakogeorgou E., Papakonstanti E., Hatzoglou A., Wallet F., Dussert C., Stournaras C., Martin P-M., CASTANAS E. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: Involvement of cytoskeletal elements. J. Cell. Biochem. 73, 204-211

 

3. Nistikaki A., Hatzoglou A., Boskou D., CASTANAS E. Potent inhibition of human breast and prostate cancer cell lines by olive oil phenolic acids. HSBMB Newslet. 46, 277-281

 

4. Chatzaki E., Makrigiannakis A., Margioris A., CASTANAS E., Gravanis A. Prodynorphin-derived κ-opioid peptides are expressed in normal and tumoral cells of human endometrium: paracrine effects on Transforming Growth Factor beta-1. HSBMB Newslet. 46, 17-19.

 

5. Kampa M., Hatzoglou A., Thermos K., CASTANAS E. Direct interaction of opioids with α1 adrenergic receptors in the human prostate cancer cell line LNCaP. Action on cell proliferation.

HSBMB Newslet. 46, 30-35

 

6. CASTANAS E. Microconstituents of olive oil and their role in health. Olive tree in past and future (in press)

 

7. Hatzoglou A., Bakogeorgou E., Kampa M., Panagiotou S., Martin P-M., Loukas S., CASTANAS E. Somatostatin and Opioid Receptors in mammary tissue: Role in cancer cell growth. Mammary Gland Biology, Raven Press, 55-63.

 

2000

 

 

1. Damianaki Α., Bakogeorgou Ε., Kampa Μ., Notas G. Hatzoglou Α., Panagiotou S., Gemetzi C., Kouroumalis E., Martin P-M., CASTANAS E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J. Cell. Biochem. 78, 429-441

 

2. Kampa M., Hatzoglou A., Notas G., Damianaki A., Bakogeorgou E., Gemetzi, C., Kouroumalis E., Martin P-M., CASTANAS E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr. Cancer 37, 105-115

 

3. Chatzaki E., Margioris A., Makrigiannakis A., CASTANAS E., Georgoulias V., Gravanis A. Kappa opioids and transforming growth factor beta1 interact in human endometrial cells. Mol. Human Reprod. 6, 610-617

4. Nikolopoulos S., Peteinaki E., CASTANAS E. Immunological Effects of Emdogainâ in humans: One year results. Int. J. Periodont. Rest. Dent. (in press)

 

5. Nikolopoulos S., Naoumidou I., Manousaki A., Theodorides D., Helidonis E., CASTANAS E. Safety of ArF-excimer laser for the removal of dental plaque and calculi: An ex-vivo histological study. J. Clin. Laser Med. Surg. 18, 295-300

 

6. Hatzoglou A., Bakogeorgou E., Kampa M., Panagiotou S., Martin P-M., Loukas S., CASTANAS E. Somatostatin and Opioid Receptors in mammary tissue: Role in cancer cell growth. Adv. Exper. Med. Biol. 480, 55-63.

 

7. Hatzoglou A., Bakogeorgou E., Damianaki A., Tsapis A., CASTANAS E. Opioids promote cell proliferation in multiple myeloma cell lines by inducing IL-6 and IL-6R. HSBMB Newsletters47, 221-223

 

8. Kampa M., Notas G., Hatzoglou A., Bakogeorgou E., Damianaki A., Kouroumalis E., CASTANAS E. Opioids inhibit Nitric Oxide Synthase in T47D human breast cancer cells. HSBMB Newsletters 47, 254-259

 

9. Hatzoglou A., Kampa M., CASTANAS E. Wine antioxidants as antiproliferative agents in homone-dependent tumors. Minutes of the meeting of the Scientific Board of the Association “Vin et Sante” (in press)

 

10. Hatzoglou A., CASTANAS E. Rules for the use of tumor markers in clinical practice. Oncology Reports (Athens) 2, 172-175

 

11. Koutroubakis I., Petinaki E., Anagnostopoulou E., Mouzas I.A., CASTANAS E., Kouroumalis E.A. Anti-saccharomyces cervisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Gut 47 (Suppl II), A232

 

 

2001

 

 

1. Kampa M., Hatzoglou A., Notas G., Niniraki M., Kouroumalis E., CASTANAS E. Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Differ. 8, 943-952

 

2. Koutroubakis J.E., Petinaki E., Mouzas I.A., Vlachonikolis I.G., Anagnostopoulou E., Maniatis A.N., CASTANAS E., Kouroumalis E.A. Anti-saccharomyces cervisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 96, 449-454

3. Nikolopoulos S., Peteinaki E., CASTANAS E. Immunological Effects of Emdogainâ in Humans: One year results. Int. J. Periodont. Rest. Dent. (in press)

 

4. Kampa M., Loukas S., Hatzoglou A., Tsapis A., CASTANAS E. Receptorphin: A new opioid peptide with kappa receptor affinity and potent antiproliferative action, derived from the sequence of the opioid receptor. BMC Pharmacology, 1, 9(1)

 

 

2002

 

1. Kampa Μ., Papakonstanti Ε.Α., Hatzoglou Α., Stathopoulos Ε.Ν., Stournaras C., Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton. FASEB J. 16, 1429-1431

 

2. Hatzoglou A., Deshayes F., Madry C., Lapree G., CASTANAS E., Tsapis A. Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue. BMC Mol. Biol 3 (1), 4

 

3. Nikolopoulos S., Peteinaki E., CASTANAS E. Immunological Effects of Emdogainâ in Humans: One year results. Int. J. Periodont. Restor. Dent. 22, 269-278

 

4. Koulentaki M. Valetas V. Xidakis K., Kouroumalis A., Petinaki E., CASTANAS E., Kouroumalis E. Matrix metalloproteinases and their inhibitors in acute viral hepatitis.
J Viral Hepat. 9, 189-93.

 

5. Hatzoglou H, Hatzoglou A, Gourgoulianis K, CASTANAS E, Molyvdas P. Rapid effects of the 17β-estradiol and progesterone in sheep pleura via a nitric oxide pathway. J Appl. Physiol. 93, 752-758

 

6. Kampa M., Nistikaki A., Tsaousis V, Maliaraki N., Notas G., CASTANAS E. A new automated method for the determination of the Total Antioxidant Capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Chemical Pathology 2: 3

 

7. Kampa M, Nistikaki A, Hatzoglou A, Kouimtzoglou H, Boskou D, Vercauteren J, Gravanis A, CASTANAS E: Phenolic acids and polyphenols are potent inhibitors of cancer cell proliferation: Assessment and mechanisms of action. In: Polyphenols 2002: Recent advances in polyphenols research. Edited by El-Hadrami I, Daayf F. Groupe Polyphenols; 2002: 62-93.

 

2003

 

1. Stathopoulos E.N., Dambaki C., Kampa M., Theodoropoulos P.A., Anezinis P., Delakas D., Delides G.S., CASTANAS E. Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. BMC, Clinical Pathology 3,1

 

2. Papakonstanti E.A., Kampa M., CASTANAS E., Stournaras C. A rapid, non-genomic, signaling pathway regulates the actin reorganization induced by membrane testosterone receptors’ activation. Mol. Endocrinology 17, 870-881

 

3. Kallergi G, Tsapara A., Kampa M., Krasagakis K., CASTANAS E., Stournaras C. Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and non-malignant MCF12A human breast epithelial cells. Exp. Cell Res 288, 94-109

 

4. Malliaraki N., Mpliamplias D., Kampa M., Margioris A.N., CASTANAS E. Total and Corrected Antioxidant Capacity in patients undergoing hemodialysis. BMC Nephrology 4:4

 

5. Boskou D., Nistikaki A., Kampa M., Hatzoglou A., Blekas G., CASTANAS E. Inhibition of human breast and prostate cancer cell lines by olive oil phenolic acids. In Bahorun T., Gurib-Fakim A. (Editors) Molecular and therapeutic aspects of redox biochemistry. OICA International (K) Ltd London pp 239-248

 

6. Ganotakis E.s., Mandalaki K., Tampakaki M., Malliaraki N., Mandalakis E., Vrentzos G., Melissas J., CASTANAS E. Subclinical hypothyroidism and Lipid abnormalities in older women attending a vascular disease prevention clinic: Effect of thyroid replacement therapy. Angiology 54: 569-576

 

2004

 

1. Kampa M., Alexaki VI., Notas G., Nifli AF., Nistikaki A., Hatzoglou A., Bakogeorgou E., Kouimtzoglou E., Blekas G., Boskou D., Gravanis A., CASTANAS E. Antiproliferative and apoptotic effects of selective Phenolic acids on T47D human breast cancer cells: Potential mechanisms of action.  Breast Cancer Res. 6: R63-R74

 

2. Alexandrakis MG., Passam FH., Kyriakou DS., Christophoridou AV., Perisinakis K., Hatzivasili A., Foudoulakis A., CASTANAS E. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol. 75: 101-106

 

3. Kampa M., Papakonstanti E., Hatzoglou A., Stournaras C., CASTANAS E. Opioids revert the rapid, non-genomic, effects of membrane testosterone receptors in the human prostate LNCaP cell line. Exp. Cell. Res. 294, 434-445

 

4. Koulentaki M., Notas G., Petinaki E., Valetas V., Mouzas I.A., Castanas E., Kouroumalis E. A. Nitric oxide and pro-inflammatory cytokines in acute hepatitis B. Eur J Intern Med. 15, 35-38.

 

5. Notas G., Kolios G., Mastrodimou N., Kampa M., Vasilaki A., Xidakis C., CASTANAS E., Thermos K., Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of Somatostatin receptors. J. Hepatol 40, 792-798

 

6. Charalampopoulos I., Tsatsanis C., Dermitzaki I., Alexaki V.I.,CASTANAS E., Margioris A.N., Gravanis A. Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medullary cells against apoptosis, via anti-apoptotic Bcl-2 proteins. Proc. Natl. Acad. Sci (USA) 101, 8209-14

 

7. Koutroubakis I.E., Malliaraki N., Dimoulios P., Karmiris K., CASTANAS E., Kouroumalis E. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig. Dis. Sci. 49, 1433-1437.

 

8. Papageorgiou M, Stiakaki E, Malliaraki N, Dimitriou H, Notas G, CASTANAS E, Kalmanti M. Decreased plasma total antioxidant capacity  in children under cancer chemotherapy. Leukemia Res. (in press)

 

9. Alexaki VI., Charalampopoulos I., Kampa M., Vassalou H., Theodoropoulos P., Hatzoglou A., Gravanis A., CASTANAS E. Estrogen exert neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J. 18, 1594-1596

 

10. Hatzoglou A., Kampa M., CASTANAS E. Opioid-somatostatin interactions in regulating cancer cell growth. Front. Biosci. 2004 Aug 3 [Epub ahead of print]

 

11. Nikolopoulos S., Naoumidou I., Nikolopoulou M. Helidonis E., CASTANAS E. ArF-193 Excimer Laser and Emdogain® in the Treatment of Experimental Periodontitis: An Experimental Study in Rabbits. Photomedicine Laser Surg 22, 357-362

 

12  Hatzoglou A., Kampa M., Kogia C., Charalampopoulos I., Theodoropoulos PA., Anezinis P., Dambaki C., Papakonstanti EA., Stathopoulos EN., Stournaras C., Gravanis A., CASTANAS E.

Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J. Clin. Endocrinol. Metab. (accepted)

 

13. Notas G., CASTANAS E., Kouroumalis E. Patients with primary biliary cirrhosis have increased serum total antoxidant capacity measured with the crocin bleaching assay. World J. Gastroenterol. (accepted)

 

14 Dambaki C., Kogia Ch., Kampa M., Theodoropoulos P., Anezinis P., CASTANAS E., Stathopoulos EN. Detection of membrane testosterone receptors in prostate cancer: A potential new multitask marker. Submitted

 

15 Notas G., Kampa M., Nifli A-P., Vercauteren J., Kouroumalis E., CASTANAS E. The system NO/NOS mediates the antiproliferative effects of wine polyphenols in HepG2 human hepatocellular carcinoma cell line. Sumbitted

 

16 Bakogeorgou E., Damnianaki A., Tsapis A., CASTANAS E., Hatzoglou A. Opioids promote IL-6 and IL-6R expression from multiple myeloma cell lines and differentially affect their growth. Submitted

 

 

2005

 

1. Hatzoglou A., Kampa M., CASTANAS E. Opioid-somatostatin interactions in regulating cancer cell growth. Front. Biosci. 10, 244-256